IZKF-Project A64

IZKF

Head of Department:
Prof. Dr. med. André Reis

SHP2 as a target for the treatment of fibrosis

Fibrotic diseases impose a major burden on modern societies and there is huge medical need for anti-fibrotic therapies. Our preliminary results demonstrate that SHP2 positively regulates TGFbeta signaling by increasing the activation JAK2 and STAT3. Inactivation of SHP2 prevents fibroblast activation and ameliorates experimental fibrosis. We aim to further characterize the molecular mechanisms of SHP2 signaling in fibroblasts and to validate SHP2 as a therapeutic target in fibrotic diseases.

Prof. Dr. Jörg Distler
phone: +49 9131 85-34742
e-mail: joerg.distler@uk-erlangen.de
business card
Prof. Dr. Georg Schett
phone: +49 9131 85-39133
e-mail: georg.schett@uk-erlangen.de
business card
 
Term

01.02.2016 - 31.07.2018

 

Project Manager

Prof. Dr. Jörg Distler

Department of Medicine 3


Prof. Dr. Georg Schett

Department of Medicine 3

 
 
 
 
Please insert your name and correct email addresses!
X zum Schließen

Summary